Two researchers/physicians out of the University of Naples Federico II—one of the oldest universities in the world—introduce the use of two drugs classically used by dermatologists for the investigational use in fighting SARS-CoV-2, the virus behind the COVID-19 pandemic. The two doctors hypothesize that the use of Hydroxychloroquine (HCQ) and Ivermectin may evidence a consequential and synergistic action if administered simultaneously both for chemoprophylaxis and treatment of COVID-19.
TrialSite News includes the source manuscript and offers below a simple and straightforward breakdown of their position.
Why is HCQ being tested in many clinical trials now against COVID-19?
The Italian doctors posit that HCQ, the antimalarial drug, is an analog of chloroquine (CQ), considered an immunomodulator rather than immunosuppressant. They note that HCQ and CQ inhibit SARS-CoV-2 in vitro, with HCQ found to be more potent than chloroquine (CQ). They go on that HCQ evidences antiviral effects at both pre-infection and post-infection stages. Moreover, they position that HCQ could interfere with glycosylation of angiotensin-converting enzyme 2, thereby reducing the...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).